COURT-RULING filed May 27, 2026 at 20:00 ET
The Federal Circuit reversed the district court's judgment and permanent injunction against EOFlow, holding that Insulet's trade secret misappropriation claim under the Defend Trade Secrets Act was time-barred because Insulet knew or should have known of the misappropriation before August 3, 2020 (three years before filing suit). The court found undisputed evidence that Insulet had knowledge of EOFlow's access to its trade secrets through a former employee and of striking similarities between the Omnipod and EOPatch 2 by early 2019, triggering the three-year statute of limitations. This ruling vacates the $59.4 million in damages (after reduction) and the permanent injunction that barred EOFlow from commercializing products using Insulet's trade secrets, removing a major overhang on EOFlow's ability to compete in the insulin patch pump market.